Fig. 4.

Allogenic islet graft rejection is ameliorated by in vivo ABT-737 treatment. 50-1/CBA nonautoimmune diabetic mice were treated daily for 14 consecutive d with either ABT-737 (50 mg/kg) or vehicle control. On treatment day 6, mice received an allogenic graft of F₁ (B6 × SJL) islets transplanted under the kidney capsule. Blood glucose was measured at various times after transplantation. Grafts were deemed successful if normal blood glucose (<15 mmol/L) levels were achieved within 4 d after transplantation. Islets grafts transplanted into ABT-737–treated recipients functioned significantly longer than grafts transplanted into vehicle control-treated recipients (no icon) (P < 0.002 as determined by a log-rank test).